Unité de Génomique Virale et Vaccination, Institut Pasteur, CNRS URA 3015, 28 rue du Dr. Roux, 75724 Paris Cedex 15, France.
Vaccine. 2013 Aug 12;31(36):3718-25. doi: 10.1016/j.vaccine.2013.05.086. Epub 2013 Jun 4.
Chikungunya virus (CHIKV), a mosquito-transmitted alphavirus, recently reemerged in the Indian Ocean, India and Southeast Asia, causing millions of cases of severe polyarthralgia. No specific treatment to prevent disease or vaccine to limit epidemics is currently available. Here we describe a recombinant live-attenuated measles vaccine (MV) expressing CHIKV virus-like particles comprising capsid and envelope structural proteins from the recent CHIKV strain La Reunion. Immunization of mice susceptible to measles virus induced high titers of CHIKV antibodies that neutralized several primary isolates. Specific cellular immune responses were also elicited. A single immunization with this vaccine candidate protected all mice from a lethal CHIKV challenge, and passive transfer of immune sera conferred protection to naïve mice. Measles vaccine is one of the safest and most effective human vaccines. A recombinant MV-CHIKV virus could make a safe and effective vaccine against chikungunya that deserves to be further tested in human trials.
基孔肯雅病毒（CHIKV）是一种通过蚊子传播的甲病毒，最近在印度洋、印度和东南亚重新出现，导致数百万人出现严重的多发性关节炎。目前尚无预防疾病的特效治疗方法或疫苗来限制疫情的爆发。在这里，我们描述了一种表达基孔肯雅病毒样颗粒的重组减毒麻疹疫苗（MV），该颗粒由来自最近的留尼汪岛 CHIKV 株的衣壳和包膜结构蛋白组成。免疫接种易感麻疹病毒的小鼠可诱导高水平的中和几种原发性分离株的 CHIKV 抗体。还引起了特异性细胞免疫反应。单次接种这种候选疫苗可使所有小鼠免受致命性 CHIKV 攻击的侵害，而免疫血清的被动转移可使无经验的小鼠得到保护。麻疹疫苗是最安全、最有效的人类疫苗之一。重组 MV-CHIKV 病毒可能成为对抗基孔肯雅热的安全有效疫苗，值得在人体试验中进一步测试。
